Adjuvant therapy in colon cancer

Oncology

Volumn 77, Issue SUPPL. 1, 2010, Pages 50-56

  Lombardi, Lucia ^a   Gebbia, Vittorio ^b   Silvestris, Nicola ^c   Testa, Antonio ^b   Colucci, Giuseppe ^c   Maiello, Evaristo ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b LA MADDALENA CANCER CENTER   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Adjuvant chemotherapy; Colon cancer; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; PANITUMUMAB; UFT; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADVANCED CANCER; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER STAGING; CAUSE OF DEATH; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG FATALITY; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; INTESTINE INJURY; INTESTINE WALL; LYMPH NODE; MICROSATELLITE INSTABILITY; NAUSEA; NEUTROPENIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSORY NEUROPATHY; STOMATITIS; ADJUVANT CHEMOTHERAPY; COLON TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS;

EID: 77949901120     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000258496     Document Type: Review

References (35)

1. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2000-cancer incidence, mortality and prevalence worldwide, version 1.0, 2000.
2. Coutinho AK, Rocha Lima CM: Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control 2003; 10: 224-238.
3. Benson AB, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-3419.
4. Greene FL, Stewart AK, Norton HJ: A new TNM tagging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002; 236: 416-421.
5. Nauta R, Stablein DM, Holyoke ED: Survival of patients with stage B2 colon carcinoma: the Gastrointetinal Tumor Study Group experience. Arch Surgery 1989; 124: 180-182.
6. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? Clin Oncol 2004; 22: 1797-1806.
7. Sobrero A, Guglielmi A, Grossi F, et al: Mechanism of action of fluoropyrimidine: relevance to the new developments in colo-rectal cancer chemotherapy. Semin Oncol 2000; 27: 72-77.
8. Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000; 321: 531-535.
9. Moertel CG, Fleming TR, Macdonal JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-358.
10. Poplin EA, Benedetti JK, Estes NC, et al: Phase III Southwest Oncology Group 9415/ Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005: 23: 1819-1825.
11. QUASAR Collaborative Group: Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colonrectal cancer: a randomized trial. Lancet 2000; 355: 1588-1596.
12. O'Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer J Clin Oncol 1998; 16: 295-300.
13. Van Cutsem E, Hoff P, Harper P, et al: Oral capecitabine versus intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trial. Br J Cancer 2004; 90: 1190-1197.
14. Cassidy J, Twelvses C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/ leucovorin. Ann Oncol 2002; 13: 566-575.
15. Twelves C, Wong A, Nowacki MP, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
16. Twelves C, Scheithauer W, McKendrick J, et al: 5-year overall survival update from XACT trial of capecitabine vs. 5-FU/LV s adjuvant treatment for stage III colon cancer 14 th European Cancer Conference (ECCO), Barcelona, Spain, 2007.
17. Lembersky BC, Wieand HS, Petrelli NJ, et al: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-06. J Clin Oncol 2006; 24: 2059-2064.
18. Andrè T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
19. de Gramont A, Boni C, Navarro M, et al: Oxaliplatin /5-FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median followup of six years. J Clin Oncol 2007; 25: 18S.
20. Andre T, Boni C, Navarro M, et al: Improved overall survival with oxaliplain, fluorouracil and leucovorin as adjuvant treatment in stage II or III coon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
21. Kuebler JP, Wieand HS, O'Connel MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: result from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204.
22. Sharif S, O'Connel MJ, Yothers G, et al: FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest 2008; 26: 956-963.
23. Boni C, Thierry A, Banzi MC, et al: Similarities and differences between the adjuvant oxaliplatin-based trials MOSAIC and NSABP C-07. Curr Colorec Cancer Reports 2009; 5: 166-170.
24. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
25. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl J Med 2000; 343: 905-914.
26. Sargent DJ, Wieand HS, O'Connel MJ, et al: Disease free-survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,989 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-8670.
27. Van Cutsem E, Labianca R, Bodoky G, et al: Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC 3. J Clin Oncol 2009; 27: 3117-3125.
28. Ychou M, Raoul JL, Douillard JY, et al: A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009; 20: 674-680.
29. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797-1806.
30. Mamounas E, Wieand S, Wolmark N, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs. Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03 and C-04). J Clin Oncol 1999; 17: 1349-1355.
31. Gray RG, Barnwell J, Hill R, et al: QUASAR: a randomized study of adjuvant chemotherapy vs. observation including 3238 colorectal cancer patients. J Clin Oncol 2004; 22 (suppl 14):245.
32. Le Voyer T, Sigurdson E, Hanlon A, et al: Colon cancer survival is associated with increasing number of lymph node analyzed: a secondary survey of Intergroup trial INT-0089. J Clin Oncol 2003; 21: 2912-2919.
33. Benson AB III, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-3419.
34. Venook AP: Epidermal growth factor receptor targeted treatment for advanced colorectal carcinoma. Cancer 2005; 103: 2435-2446.
35. Wolmark N, Yothers G, O'Connell MJ, et al: A phase III trial comparing mFOLFOX6 to m FOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol 2009; 27(suppl 15):793s.